商品詳細

Biocompatible Nanomaterials in Immuno-Oncology: Eco-Friendly Drug Delivery Solutions explores the convergence of nanotechnology, immunology, and sustainable pharmaceutical sciences to address critical challenges in modern cancer therapy. Although immuno-oncology has revolutionized cancer treatment through immune checkpoint inhibitors, cancer vaccines, adoptive cell therapies, and monoclonal antibodies, their clinical success is often limited by poor tumor targeting, systemic toxicity, immune-related adverse effects, and variable patient responses.

This volume highlights the potential of biodegradable and biocompatible nanomaterials as advanced drug delivery platforms capable of enhancing the safety, precision, and therapeutic efficacy of immunotherapies. Particular emphasis is placed on naturally derived nanocarriers, including polysaccharides, proteins, lipids, and plant-based polymers, which offer excellent biocompatibility, biodegradability, and reduced environmental impact compared with conventional synthetic materials.

A key focus of the book is the development of eco-friendly nanoparticle fabrication strategies based on green chemistry principles, utilizing plant extracts, microorganisms, and other renewable biological resources. The chapters discuss innovative nanoplatforms for the targeted delivery of immune checkpoint inhibitors, cytokines, nucleic acids, peptides, proteins, and cancer vaccines, while addressing tumor microenvironment modulation and precision therapeutic approaches. Emerging topics such as biomimetic nanoparticles, stimuli-responsive systems, extracellular vesicle-inspired carriers, and artificial intelligence-enabled nanomedicine are also explored.

The book further examines translational aspects, including manufacturing, quality control, biosafety, regulatory considerations, clinical translation, and commercialization. Written by leading experts across pharmaceutical sciences, oncology, immunology, biomaterials, and nanotechnology, this volume serves as a comprehensive resource for researchers, clinicians, graduate students, industry professionals, and policymakers committed to advancing sustainable, safe, and effective nanotechnology-driven immuno-oncology.